Terms: = Ovarian cancer AND ABCG2, ABC15, ABCP, BCRP, BCRP1, BMDP, CD338, CDw338, EST157481, GOUT1, MRX, MXR, MXR-1, MXR1, UAQTL1
134 results:
1. Adipocyte‑rich microenvironment promotes chemoresistance via upregulation of peroxisome proliferator‑activated receptor gamma/abcg2 in epithelial ovarian cancer.
Chen S; Liu Z; Wu H; Wang B; Ouyang Y; Liu J; Zheng X; Zhang H; Li X; Feng X; Li Y; Shen Y; Zhang H; Xiao B; Yu C; Deng W
Int J Mol Med; 2024 Apr; 53(4):. PubMed ID: 38426604
[TBL] [Abstract] [Full Text] [Related]
2. Overexpression of ABCC1 and abcg2 confers resistance to talazoparib, a poly (ADP-Ribose) polymerase inhibitor.
Teng QX; Lei ZN; Wang JQ; Yang Y; Wu ZX; Acharekar ND; Zhang W; Yoganathan S; Pan Y; Wurpel J; Chen ZS; Fang S
Drug Resist Updat; 2024 Mar; 73():101028. PubMed ID: 38340425
[TBL] [Abstract] [Full Text] [Related]
3. The effect of paclitaxel- and fisetin-loaded PBM nanoparticles on apoptosis and reversal of drug resistance gene abcg2 in ovarian cancer.
McFadden M; Singh SK; Kinnel B; Varambally S; Singh R
J Ovarian Res; 2023 Nov; 16(1):220. PubMed ID: 37990267
[TBL] [Abstract] [Full Text] [Related]
4. Dual Targeted Nanoparticles for the Codelivery of Doxorubicin and siRNA Cocktails to Overcome ovarian cancer Stem Cells.
Chen L; Luo J; Zhang J; Wang S; Sun Y; Liu Q; Cheng C
Int J Mol Sci; 2023 Jul; 24(14):. PubMed ID: 37511335
[TBL] [Abstract] [Full Text] [Related]
5. LncRNA RBAT1 reduces chemosensitivity of cancer cells to carboplatin/paclitaxel by sponging miR‑27b in endometrial carcinoma.
Fan L; Wang C; Zhan P; Liu Y
J Ovarian Res; 2023 Jul; 16(1):147. PubMed ID: 37501162
[TBL] [Abstract] [Full Text] [Related]
6. CD109 Promotes Drug Resistance in A2780 ovarian cancer Cells by Regulating the STAT3-NOTCH1 Signaling Axis.
Kim JS; Shin MJ; Lee SY; Kim DK; Choi KU; Suh DS; Kim D; Kim JH
Int J Mol Sci; 2023 Jun; 24(12):. PubMed ID: 37373457
[TBL] [Abstract] [Full Text] [Related]
7. Genetically Engineered Artificial Exosome-Constructed Hydrogel for ovarian cancer Therapy.
Li Q; Song Q; Zhao Z; Lin Y; Cheng Y; Karin N; Luan Y
ACS Nano; 2023 Jun; 17(11):10376-10392. PubMed ID: 37194951
[TBL] [Abstract] [Full Text] [Related]
8. H1.0 induces paclitaxel-resistance genes expression in ovarian cancer cells by recruiting GCN5 and androgen receptor.
Kohli A; Huang SL; Chang TC; Chao CC; Sun NK
Cancer Sci; 2022 Aug; 113(8):2616-2626. PubMed ID: 35639349
[TBL] [Abstract] [Full Text] [Related]
9. The Profile of MicroRNA Expression and Potential Role in the Regulation of Drug-Resistant Genes in Doxorubicin and Topotecan Resistant ovarian cancer Cell Lines.
Stasiak P; Kaźmierczak D; Jopek K; Nowicki M; Rucinski M; Januchowski R
Int J Mol Sci; 2022 May; 23(10):. PubMed ID: 35628654
[TBL] [Abstract] [Full Text] [Related]
10. Effect of
Nowacka M; Ginter-Matuszewska B; Świerczewska M; Sterzyńska K; Nowicki M; Januchowski R
Int J Mol Sci; 2022 Mar; 23(6):. PubMed ID: 35328460
[TBL] [Abstract] [Full Text] [Related]
11. Piperine Targets Different Drug Resistance Mechanisms in Human ovarian cancer Cell Lines Leading to Increased Sensitivity to Cytotoxic Drugs.
Wojtowicz K; Sterzyńska K; Świerczewska M; Nowicki M; Zabel M; Januchowski R
Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33921897
[TBL] [Abstract] [Full Text] [Related]
12. Aberrant activation of Wnt/catenin signaling and overexpression of abcg2 contributes to apoptosis down regulation and tumor progression of high grade ovarian cancer.
Gui Z; Yan H; Wu J; Zhang M; Wu A; He J
Acta Biochim Pol; 2021 Feb; 68(1):127-133. PubMed ID: 33635609
[TBL] [Abstract] [Full Text] [Related]
13. Low expression of FXYD5 reverses the cisplatin resistance of epithelial ovarian cancer cells.
Liu YK; Jia YJ; Liu SH; Shi HJ; Ma J
Histol Histopathol; 2021 May; 36(5):535-545. PubMed ID: 33570156
[TBL] [Abstract] [Full Text] [Related]
14. Effect of ABC transporter expression and mutational status on survival rates of cancer patients.
Kadioglu O; Saeed MEM; Munder M; Spuller A; Greten HJ; Efferth T
Biomed Pharmacother; 2020 Nov; 131():110718. PubMed ID: 32932043
[TBL] [Abstract] [Full Text] [Related]
15. Pharmacogenetic score predicts overall survival, progression-free survival and platinum sensitivity in ovarian cancer.
Gagno S; Bartoletti M; Romualdi C; Poletto E; Scalone S; Sorio R; Zanchetta M; De Mattia E; Roncato R; Cecchin E; Giorda G; Toffoli G
Pharmacogenomics; 2020 Sep; 21(14):995-1010. PubMed ID: 32894980
[No Abstract] [Full Text] [Related]
16. A novel taxane, difluorovinyl-ortataxel, effectively overcomes paclitaxel-resistance in breast cancer cells.
Rong D; Wang C; Zhang X; Wei Y; Zhang M; Liu D; Farhan H; Momen Ali SA; Liu Y; Taouil A; Guo W; Wang Y; Ojima I; Yang S; Wang H
Cancer Lett; 2020 Oct; 491():36-49. PubMed ID: 32730778
[TBL] [Abstract] [Full Text] [Related]
17. The carotenoid fucoxanthin can sensitize multidrug resistant cancer cells to doxorubicin via induction of apoptosis, inhibition of multidrug resistance proteins and metabolic enzymes.
Eid SY; Althubiti MA; Abdallah ME; Wink M; El-Readi MZ
Phytomedicine; 2020 Oct; 77():153280. PubMed ID: 32712543
[TBL] [Abstract] [Full Text] [Related]
18. Adipocytes induce the resistance of ovarian cancer to carboplatin through ANGPTL4.
Zhou S; Wang R; Xiao H
Oncol Rep; 2020 Sep; 44(3):927-938. PubMed ID: 32705217
[TBL] [Abstract] [Full Text] [Related]
19. A novel c-Kit/phospho-prohibitin axis enhances ovarian cancer stemness and chemoresistance via Notch3-PBX1 and β-catenin-abcg2 signaling.
Fang CH; Lin YT; Liang CM; Liang SM
J Biomed Sci; 2020 Mar; 27(1):42. PubMed ID: 32169072
[TBL] [Abstract] [Full Text] [Related]
20. MRP1 modulators synergize with buthionine sulfoximine to exploit collateral sensitivity and selectively kill MRP1-expressing cancer cells.
Gana CC; Hanssen KM; Yu DMT; Flemming CL; Wheatley MS; Conseil G; Cole SPC; Norris MD; Haber M; Fletcher JI
Biochem Pharmacol; 2019 Oct; 168():237-248. PubMed ID: 31302132
[TBL] [Abstract] [Full Text] [Related]
[Next]
